Drugs / CVX-060
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00879684 | Jan 2008 → Apr 2011 | carcinoma | Pfizer | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01441414 | Nov 2011 → Mar 2014 | renal cell carcinoma | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT01225510 | Jan 2011 → Jan 2013 | glioblastoma | Pfizer | Withdrawn | No outcome recorded |
| Phase 2 | NCT00982657 | Sep 2009 → Mar 2014 | cancer | Pfizer | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CVX-060 | “A PHASE II TRIAL OF PF-04856884 (CVX-060), A SELECTIVE ANGIOPOIETIN-2 (ANG-2) INHIBITOR IN COMBINATION WITH AG-013736 (AXITINIB) IN PATIENTS WITH PREVIOUSLY TREATED METASTATIC...” NCT01441414 ↗ |
| Known as | PF-04856884 | “Subsequently, on 25-Oct-2012, due to data safety signals in a separate clinical trial with PF-04856884 (CVX-060), all PF-04856884 studies were discontinued and ongoing patients...” NCT00982657 ↗ |
| Action | Inhibit | “PF-04856884 (CVX-060) is a compound which binds Ang-2 and prevents its activity.” NCT01225510 ↗1“Angiopoietin-2 inhibitor” CHEMBL4594470 ↗ |
| Modality | Protein / enzyme biologic | “Anti-angiogenic Covx-body” NCT00879684 ↗ |
| Route | Intravenous | “Weekly, intravenous dose” NCT00879684 ↗ |
| Target | ANGPT2 | “Angiopoietin-2 inhibitor” CHEMBL4594470 ↗ |